Mirnax Biosens ^company

The personalized diagnosis, prognosis and treatment management of cardiovascular diseases, cancer, acute renal failure and hepatic pathology or asthma, among others, could be known sooner by measuring biomarkers linked to these diseases. Mirnax Biosens, S.L. is a biotechnology company, owned by Canaan Research & Investment, focused on development of new disruptive technologies based on liquid biopsy in area of clinical diagnosis and prognosis. MIRNAX is developing an universal and innovative platform of genetic biomarkers validation which have different biological nature (DNA, RNA, miRNAs, lncRNA, etc.) to market a technology, based on microqPCR, that can give a personalized diagnosis and prognosis response in a fast and effective way. This new technology of Mirnax gives rise to the development of different diagnosis and prognosis kits which are unique and innovative in the current market and they generate a personalized response to each patient. Our society owns several biomarker signatures with clinical value and excellent commercial perspectives. They allow the development of kits for pathologies with high incidence in current population and pathologies without diagnosis and prognosis options. Among them, there is a biomarkers group biomarkers to detecting Acute Kidney Injury in the early stages, which has been developed in collaboration with IRYCIS; a biomarker to know treatment response in patients with Rheumatoid Arthritis, of IMIBIC and a biomarker to diagnosis asthma and patients stratification, of Jimenez Diaz Foundation. In addition, MIRNAX has developed, in collaboration with Complutense University of Madrid, automated equipment (electrochemical biosensor). With it, several blood biomarkers have been validated for diseases such as cancer, cardiomyopathies, rheumatoid arthritis, asthma, kidney injury or liver failure, as well as another groups of biomarkers to detect oral cancer (mouth, lips, tongue or salivary glands cancer) directly from a sample of spit.